INTERGRATED DIA.H DL 025
Integrated Diagnostics Holdings plc operates as a consumer healthcare company that provides medical diagnostics services to patients. It offers approximately 3,000 diagnostic pathology tests, such as immunology, microbiology, haematology, endocrinology, clinical chemistry, molecular biology, parasitology, histopathology, and genetics. The company also provides radiology services, such as positron… Read more
INTERGRATED DIA.H DL 025 (8I8) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, INTERGRATED DIA.H DL 025 (8I8) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
INTERGRATED DIA.H DL 025 - Net Assets Trend (None–None)
This chart illustrates how INTERGRATED DIA.H DL 025's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for INTERGRATED DIA.H DL 025 (None–None)
The table below shows the annual net assets of INTERGRATED DIA.H DL 025 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to INTERGRATED DIA.H DL 025's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
INTERGRATED DIA.H DL 025 Competitors by Market Cap
The table below lists competitors of INTERGRATED DIA.H DL 025 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dongnan Electronics Co. Ltd. A
SHE:301359
|
$112.45 Million |
|
RF Industries Ltd
NASDAQ:RFIL
|
$112.45 Million |
|
Shaanxi Meibang Pharmaceutical Group Co Ltd
SHG:605033
|
$112.46 Million |
|
Mnc Investama Tbk
JK:BHIT
|
$112.48 Million |
|
Century Therapeutics Inc
NASDAQ:IPSC
|
$112.43 Million |
|
AM Locales Property Socimi
MC:YAML
|
$112.34 Million |
|
American Oncology Network Inc.
NASDAQ:AONC
|
$112.23 Million |
|
Shinsegae Inte
KO:031430
|
$112.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in INTERGRATED DIA.H DL 025's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares INTERGRATED DIA.H DL 025's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently INTERGRATED DIA.H DL 025 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares INTERGRATED DIA.H DL 025's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $10,792,710,184
- Average return on equity (ROE) among peers: -33.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| INTERGRATED DIA.H DL 025 (8I8) | €- | N/A | N/A | $112.44 Million |
| Spermosens AB (publ) (9R5) | $23.64 Million | -27.17% | 0.09x | $517.28K |
| BML Inc (BMZ) | $81.13 Billion | 8.19% | 0.43x | $462.01 Million |
| Genomic Vision Société Anonyme (G09) | $3.07 Million | -162.85% | 1.21x | $711.54K |
| ICON Public Limited Company (IJF) | $1.85 Billion | 17.96% | 0.86x | $6.43 Billion |
| Adicon Holdings Limited (K0U) | $1.77 Billion | 2.65% | 1.64x | $138.53 Million |
| WuXi XDC Cayman Inc. (L74) | $1.48 Billion | 10.52% | 0.69x | $2.11 Billion |
| NanoRepro AG (NN6) | $57.61 Million | 51.59% | 0.37x | $16.84 Million |
| PERRIGO (PGO) | $24.67 Million | -167.93% | 0.99x | $6.37K |